Dr. Lior Mayo PhD
Sagol School of Neuroscience
Shmunis School of Biomedicine and Cancer Research
George S. Wise Faculty of Life Sciences
Tel Aviv University
Tel Aviv, Israel

Dr. Lior Mayo obtained his Ph.D. from the Department of Neurobiochemistry at Tel Aviv University, studying brain diseases’ underlying mechanisms. Continuing this theme during his post-doctoral training at Harvard Medical School, Dr. Mayo explored a novel role for lipids in the progressive phase of Multiple Sclerosis and identified novel regulatory circuits, which were the basis for the development of Foralumab Dr. Mayo joined the Shmunis School of Biomedicine and Cancer Research and the Sagol School of Neuroscience in 2016, establishing the Autoimmunity and Neuroimmunology Laboratory. Dr. Mayo is the Director of Tel-Aviv University’s Research Hub in Immunity and Inflammation. Dr. Mayo is the recipient of the National Multiple Sclerosis Society Transition Award, the Gesher for Excellence in Cancer Research of the Israel Cancer Research Fund, the Neufeld Award for the most outstanding and original project in the health sciences (2020) of the National U.S.-Israel Binational Science Foundation, and the Dr. Philip Moskowitz prize for Outstanding Research Achievement in Autoimmunity form the Colton foundation.

Dr. Mayo’s team strives to understand the intracellular communication and molecular immunometabolic mechanisms that underlie neurologic diseases and translate these laboratory discoveries into new therapies. Currently, Mayo’s team investigates different applications of gene and cell-based therapies to treat neurodegenerative diseases, such as multiple sclerosis and Parkinson’s disease, and halt the progression of brain tumors.